BioArctic

BioArctic Debt Growth

The Year-over-Year Debt Growth of BioArctic (BIOA B.ST) as of Nov 5, 2026 is -18.73 %. In the previous year, Year-over-Year Debt Growth was 989.13 % — a change of -101.89% (lower).

Debt Growth

-18.73 %

YoY

-101.89%

Last updated:

Year-over-Year Debt Growth of BioArctic is 2025 -18.73 % . Year-over-Year Debt Growth of BioArctic was 2024 989.13 % . It decreases by -101.89% lower compared to the previous year.

The BioArctic Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
55.82 SEK
Jan 1, 2019
113.09 SEK
Jan 1, 2020
-24.11 SEK
Jan 1, 2021
-23.55 SEK
Jan 1, 2022
-36.77 SEK
Jan 1, 2023
-50.40 SEK
Jan 1, 2024
989.13 SEK
Jan 1, 2025
-18.73 SEK
The BioArctic Debt Growth history
YEARDebt GrowthYoY
-18.73 %-101.89%
989.13 %-2,062.43%
-50.40 %+37.08%
-36.77 %+56.13%
-23.55 %-2.32%
-24.11 %-121.32%
113.09 %+102.60%
55.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Year-over-Year Debt Growth of BioArctic is -18.73 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth BioArctic since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioArctic

All Key Metrics — BioArctic